...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Heart >Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
【24h】

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)

机译：美托洛尔和卡维地洛对慢性心力衰竭患者先前和新发糖尿病的影响：来自卡维地洛或美托洛尔欧洲试验（COMET）的数据

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: β Blocker treatment may worsen glucose metabolism.rnObjective: To study the development of new onset diabetes in a large cohort of patients with heart failurerntreated with either metoprolol or carvedilol.rnDesign: Prospective and retrospective analysis of a controlled clinical trial.rnSetting: Multinational multicentre study.rnPatients: 3029 patients with chronic heart failure.rnInterventions: Randomly assigned treatment with carvedilol (n = 1511, target dose 50 mg daily) orrnmetoprolol tartrate (n = 1518, target dose 100 mg daily).rnResults: Diabetic events (diabetic coma, peripheral gangrene, diabetic foot, decreased glucose tolerance orrnhyperglycaemia) and new onset diabetes (clinical diagnosis, repeated high random glucose level or glucosernlowering drugs) were assessed in 2298 patients without diabetes at baseline. Diabetic events occurred inrn122/1151 (10.6%) patients in the carvedilol group and 149/1147(13.0%) patients in the metoprolol grouprn(hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.61 to 0.99; p = 0.039). New onset diabetes wasrndiagnosed in 119/1151 (10.3%) v 145/1147 (12.6%) cases in the carvedilol and metoprolol treatmentrngroups (HR = 0.78, CI 0.61 to 0.997; p = 0.048), respectively. Patients with diabetes at baseline had anrnincreased mortality compared with non-diabetic subjects (45.3% v 33.9%; HR= 1.45, CI 1.28 to 1.65). Bothrndiabetic and non-diabetic subjects at baseline had a similar reduction in mortality with carvedilol comparedrnwith metoprolol (RR = 0.85; CI 0.69 to 1.06 and RR = 0.82; CI 0.71 to 0.94, respectively).rnConclusion: A high prevalence and incidence of diabetes is found in patients with heart failure over a coursernof 5 years. New onset diabetes is more likely to occur during treatment with metoprolol than during treatmentrnwith carvedilol.
机译：背景：β受体阻滞剂治疗可能会使葡萄糖代谢恶化。目的：研究在大量接受美托洛尔或卡维地洛治疗的心力衰竭患者中新发糖尿病的发生。设计：对一项对照临床试验的前瞻性和回顾性分析。研究背景：跨国公司多中心研究。患者：3029例慢性心力衰竭患者。干预：随机分配卡维地洛（n = 1511，目标剂量每天50 mg）或酒石酸美托洛尔（n = 1518，目标剂量每天100 mg）。rn结果：糖尿病事件（糖尿病）在基线时对2298例无糖尿病的患者进行了昏迷，周围坏疽，糖尿病足，葡萄糖耐量降低或高血糖症的发生和新发糖尿病（临床诊断，反复的随机高血糖水平或降糖药）的评估。卡维地洛组的糖尿病事件发生在rn122 / 1151（10.6％）患者和美托洛尔组的149/1147（13.0％）患者中（危险比（HR）= 0.78; 95％置信区间（CI）0.61至0.99; p = 0.039）。卡维地洛和美托洛尔治疗组（HR = 0.78，CI 0.61至0.997； p = 0.048）分别被诊断为119/1151（10.3％）v 145/1147（12.6％）的新发糖尿病。与非糖尿病患者相比，基线时患有糖尿病的患者死亡率增加（45.3％对33.9％； HR = 1.45，CI 1.28至1.65）。卡维地洛与美托洛尔相比，基线时糖尿病患者和非糖尿病患者的死亡率都有相似的降低（RR = 0.85； CI为0.69至1.06和RR = 0.82； CI为0.71至0.94）。结论：糖尿病的高患病率和发病率是在5年的课程中发现于心力衰竭患者中。美托洛尔治疗期间比卡维地洛治疗期间更容易发生新发糖尿病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号